Middle East & Africa Bioproduction Market Forecast to 2030 - Regional Analysis - by Product, Application, Equipment, and End User

The Middle East & Africa bioproduction market was valued at US$ 283.68 million in 2022 and is expected to reach US$ 652.96 million by 2030; it is estimated to register a CAGR of 11.0% from 2022 to 2030.

Shift Toward Automated Cell Therapy Manufacturing Bolsters Middle East & Africa Bioproduction Market

Automation can deliver many benefits for cell therapy developers, including reduced risk of contamination, improved consistency, and reduced cost of production. Many companies have offered devices to enable automation, such as the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. A rising number of cell therapies have shifted the production of cell therapy products from a small volume to a large volume worldwide. In addition, the evolution of cell therapy, from an academic and clinical setting to mass production and commercialization, is increasing the demand for automation in manufacturing. Increasing research activities in cell therapies have led to a rise in demand for advanced manufacturing solutions. In view of this, many players are offering products to meet the digital needs of academic researchers and large biotechnology companies. For instance, in May 2019, GE Healthcare launched the Chronicle web application to support the complete cell therapy workflow. Chronicle automation software is a good manufacturing practice (GMP)-compliant digital solution designed to optimize complex cell therapy process development and manufacturing.

Companies are also entering into strategic and technological developments for automation in cell therapy. For instance, in July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the fitness of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software) along with reagents, consumables, and instruments. Thus, the increasing adoption of automation among cell therapy manufacturers is anticipated to drive the market.

Middle East & Africa Bioproduction Market Overview

The bioproduction market in the Middle East & Africa includes a country-level analysis of the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The bioproduction market growth can be attributed to changing government policies, increasing private-public partnerships, and improving healthcare infrastructure. Moreover, the increasing demand for advanced and effective cell therapies is facilitating the market growth.

According to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), cardiovascular disease was the foremost cause of death in Saudi Arabia in 2020, accounting for 45.7% of all death cases. Further, there is a high prevalence of diabetes in Saudi Arabia due to unhealthy eating habits and sedentary lifestyles. According to IDF, the frequency rate of diabetes in Saudi Arabia ranged from 8% to 22% in 2021. The factors majorly contributing to diabetes are obesity, unhealthy lifestyle, and genetic susceptibility. According to a nationwide survey, Saudi Arabia had 5.5% of cardiovascular disease prevalence in 2022. Thus, the growing incidence rate of cardiovascular diseases and diabetes in Saudi Arabia is driving the growth of the bioproduction market.

Middle East & Africa Bioproduction Market Segmentation

The Middle East & Africa bioproduction market is categorized into product, application, equipment, end user, and country.

Based on product, the Middle East & Africa bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest Middle East & Africa bioproduction market share in 2022.

In terms of application, the Middle East & Africa bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest Middle East & Africa bioproduction market share in 2022.

By equipment, the Middle East & Africa bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest Middle East & Africa bioproduction market share in 2022.

In terms of end user, the Middle East & Africa bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest Middle East & Africa bioproduction market share in 2022.

By country, the Middle East & Africa bioproduction market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa bioproduction market share in 2022.

Lonza Group AG, Danaher Corp, Sartorius AG, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the Middle East & Africa bioproduction market.